30 minutes
Biotech is not for the risk averse. Most successful entrepreneurs and investors have experienced multiple failures on their way to commercialization, and many have had to scrap what they were working on and start over. Beyond the statistics of scientific and clinical results missing desired endpoints, hear the personal stories of those who have lived the ups and downs of the long journey from intriguing science to patient bedside.
